EDP-322
Phase 1Completed 0 watching 0 views this week💤 Quiet
25
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
MRSA, SSTI
Conditions
MRSA, SSTI
Trial Timeline
Nov 1, 2008 → Sep 1, 2009
NCT ID
NCT00990145About EDP-322
EDP-322 is a phase 1 stage product being developed by Enanta Pharmaceuticals for MRSA, SSTI. The current trial status is completed. This product is registered under clinical trial identifier NCT00990145. Target conditions include MRSA, SSTI.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00989872 | Phase 1 | Completed |
| NCT00990145 | Phase 1 | Completed |
Competing Products
4 competing products in MRSA, SSTI
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Chlorhexidine gluconate soap + Chlorhexidine gluconate oral rinse + Mupirocin calcium 2 % ointment | Johnson & Johnson | Approved | 85 |
| linezolid (Zyvox) + vancomycin | Pfizer | Approved | 84 |
| Linezolid + Vancomycin | Pfizer | Pre-clinical | 22 |
| Vancomycin inhalation powder + Placebo inhalation powder + Vancomycin inhalation powder | Savara | Phase 3 | 72 |